145 related articles for article (PubMed ID: 23224565)
1. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients.
Blank S; Stange A; Sisic L; Roth W; Grenacher L; Sterzing F; Burian M; Jäger D; Büchler M; Ott K
Langenbecks Arch Surg; 2013 Feb; 398(2):211-20. PubMed ID: 23224565
[TBL] [Abstract][Full Text] [Related]
2. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
[TBL] [Abstract][Full Text] [Related]
3. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor.
Ott K; Blank S; Becker K; Langer R; Weichert W; Roth W; Sisic L; Stange A; Jäger D; Büchler M; Siewert JR; Lordick F
Langenbecks Arch Surg; 2013 Feb; 398(2):239-49. PubMed ID: 23269519
[TBL] [Abstract][Full Text] [Related]
4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
5. [Analysis of clinicopathological characteristics and prognosis on 42 patients with primary gastric adenosquamous cell carcinoma].
Li B; Sun L; Wang X; Deng J; Ding X; Wang X; Ke B; Zhang L; Zhang R; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Feb; 20(2):207-212. PubMed ID: 28226357
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
[TBL] [Abstract][Full Text] [Related]
7. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
8. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
Blank S; Rachakonda S; Keller G; Weichert W; Lordick F; Langer R; Springfeld C; Bruckner T; Becker K; Kumar R; Ott K
BMC Cancer; 2014 Feb; 14():58. PubMed ID: 24490800
[TBL] [Abstract][Full Text] [Related]
9. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
10. Comparison of mediastinal lymph node metastases from adenocarcinoma of the esophagogastric junction versus lower esophageal squamous cell carcinoma with involvement of the esophagogastric junction.
Mine S; Watanabe M; Kumagai K; Okamura A; Yuda M; Hayami M; Yamashita K; Imamura Y; Ishizuka N
Dis Esophagus; 2019 Dec; 32(11):. PubMed ID: 30791046
[TBL] [Abstract][Full Text] [Related]
11. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of clinicopathological features and prognosis between adenocarcinoma of esophagogastric junction and adenocarcinoma of gastric antrum].
Zhu Z; Wang Y; Li F; Gao J; Han B; Wang R; Xue Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):149-155. PubMed ID: 30799537
[TBL] [Abstract][Full Text] [Related]
13. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer.
Reim D; Gertler R; Novotny A; Becker K; zum Büschenfelde CM; Ebert M; Dobritz M; Langer R; Hoefler H; Friess H; Schumacher C
Ann Surg Oncol; 2012 Jul; 19(7):2108-18. PubMed ID: 22130620
[TBL] [Abstract][Full Text] [Related]
14. Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction.
Reynolds JV; Ravi N; Muldoon C; Larkin JO; Rowley S; O'Byrne K; Hollywood D; O'Toole D
World J Surg; 2010 Dec; 34(12):2821-9. PubMed ID: 20827475
[TBL] [Abstract][Full Text] [Related]
15. The preoperative neutrophil-lymphocyte ratio predicts recurrence and survival among patients undergoing R0 resections of adenocarcinomas of the esophagogastric junction.
Yuan D; Zhu K; Li K; Yan R; Jia Y; Dang C
J Surg Oncol; 2014 Sep; 110(3):333-40. PubMed ID: 24889121
[TBL] [Abstract][Full Text] [Related]
16. Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation.
Blank S; Lordick F; Bader F; Burian M; Dobritz M; Grenacher L; Becker K; Weichert W; Langer R; Sisic L; Stange A; Jäger D; Büchler M; Bruckner T; Siewert J; Ott K
Gastric Cancer; 2015 Apr; 18(2):314-25. PubMed ID: 24722800
[TBL] [Abstract][Full Text] [Related]
17. What to do after R1-resection of adenocarcinomas of the esophagogastric junction?
Gertler R; Richter J; Stecher L; Nitsche U; Feith M
J Surg Oncol; 2016 Sep; 114(4):428-33. PubMed ID: 27333949
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological features and prognostic factors of adenocarcinoma of the esophagogastric junction according to Siewert classification: experiences at a single institution in Japan.
Hosokawa Y; Kinoshita T; Konishi M; Takahashi S; Gotohda N; Kato Y; Daiko H; Nishimura M; Katsumata K; Sugiyama Y; Kinoshita T
Ann Surg Oncol; 2012 Feb; 19(2):677-83. PubMed ID: 21822549
[TBL] [Abstract][Full Text] [Related]
19. Multidisciplinary approach to esophageal and gastric cancer.
Stein HJ; Sendler A; Fink U; Siewert JR
Surg Clin North Am; 2000 Apr; 80(2):659-82; discussions 683-6. PubMed ID: 10836011
[TBL] [Abstract][Full Text] [Related]
20. Is pathological complete response after a trimodality therapy, a predictive factor of long-term survival in locally-advanced esophageal cancer? Results of a retrospective monocentric study.
Francoual J; Lebreton G; Bazille C; Galais MP; Dupont B; Alves A; Lubrano J; Morello R; Menahem B
J Visc Surg; 2018 Oct; 155(5):365-374. PubMed ID: 29501383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
